Lagenstein I, Blaschke-Zimmermann E, Iffland E, Sternowsky H J, Fehr R
Fortschr Med. 1977 Apr 7;95(13):892-6.
79 patients with primary generalized epilepsies have been treated with DPA in a medium dosage of 51 mg/kg bodyweight/day, range 14 to 125 mg/kg/day, for a medium time of 22 months, range 2 to 49 months. 51 children out of this group had been treated previously and were therapy resistant to other medications. 27 children got DPA for their first medication. 34 patients were treated with DPA as a single drug, 45 were treated in combination with other medications. Therapeutic success was found to be remarkable good in impulsive petit mal (n = 4, all patients without any more seizures), in absences (n = 52, complete success in 84%), and in primary generalized grand mal seizures with spike-waves in the EEG alone or in combination with petit mal (n = 30, 87% success). However, centrencephalic myoclonic-astatic seizures (n = 17, no more seizures in 35%) were influenced significantly less. Side effects were rarely seen, mostly they could be observed in those patients treated with DPA and another medication. Side effects never induced interruption of treatment with DPA.
79例原发性全身性癫痫患者接受了二丙基乙酸（DPA）治疗，剂量为51毫克/千克体重/天，范围为14至125毫克/千克/天，治疗时间平均为22个月，范围为2至49个月。该组中有51名儿童此前接受过治疗，对其他药物治疗耐药。27名儿童首次使用DPA治疗。34例患者使用DPA单药治疗，45例患者与其他药物联合治疗。结果发现，在冲动性小发作（n = 4，所有患者均无癫痫发作）、失神发作（n = 52，84%完全成功）以及脑电图仅有尖波或伴有小发作的原发性全身性大发作（n = 30，87%成功）中，治疗效果显著良好。然而，中央脑性肌阵挛 - 无张力性发作（n = 17，35%无癫痫发作）受影响明显较小。副作用很少见，大多出现在接受DPA与其他药物联合治疗的患者中。副作用从未导致DPA治疗中断。
